β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol

Surya P Bhatt, John E Connett, Helen Voelker, Sarah M Lindberg, Elizabeth Westfall, J Michael Wells, Stephen C Lazarus, Gerard J Criner, Mark T Dransfield, Surya P Bhatt, John E Connett, Helen Voelker, Sarah M Lindberg, Elizabeth Westfall, J Michael Wells, Stephen C Lazarus, Gerard J Criner, Mark T Dransfield

Abstract

Introduction: A substantial majority of chronic obstructive pulmonary disease (COPD)-related morbidity, mortality and healthcare costs are due to acute exacerbations, but existing medications have only a modest effect on reducing their frequency, even when used in combination. Observational studies suggest β-blockers may reduce the risk of COPD exacerbations; thus, we will conduct a randomised, placebo-controlled trial to definitively assess the impact of metoprolol succinate on the rate of COPD exacerbations.

Methods and analyses: This is a multicentre, placebo-controlled, double-blind, prospective randomised trial that will enrol 1028 patients with at least moderately severe COPD over a 3-year period. Participants with at least moderate COPD will be randomised in a 1:1 fashion to receive metoprolol or placebo; the cohort will be enriched for patients at high risk for exacerbations. Patients will be screened and then randomised over a 2-week period and will then undergo a dose titration period for the following 6 weeks. Thereafter, patients will be followed for 42 additional weeks on their target dose of metoprolol or placebo followed by a 4-week washout period. The primary end point is time to first occurrence of an acute exacerbation during the treatment period. Secondary end points include rates and severity of COPD exacerbations; rate of major cardiovascular events; all-cause mortality; lung function (forced expiratory volume in 1 s (FEV1)); dyspnoea; quality of life; exercise capacity; markers of cardiac stretch (pro-NT brain natriuretic peptide) and systemic inflammation (high-sensitivity C reactive protein and fibrinogen). Analyses will be performed on an intent-to-treat basis.

Ethics and dissemination: The study protocol has been approved by the Department of Defense Human Protection Research Office and will be approved by the institutional review board of all participating centres. Study findings will be disseminated through presentations at national and international conferences and publications in peer-reviewed journals.

Trial registration number: NCT02587351; Pre-results.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

References

    1. Blanchette CM, Dalal AA, Mapel D. Changes in COPD demographics and costs over 20 years. J Med Econ 2012;15:1176–82. 10.3111/13696998.2012.713880
    1. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4:502–6. 10.1513/pats.200701-001FM
    1. Puhan MA, Bachmann LM, Kleijnen J et al. . Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009;7:2 10.1186/1741-7015-7-2
    1. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013;162:237–51. 10.1016/j.trsl.2013.05.001
    1. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2:8–11. 10.1513/pats.200404-032MS
    1. Patel AR, Kowlessar BS, Donaldson GC et al. . Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1091–9. 10.1164/rccm.201306-1170OC
    1. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489–97. 10.1056/NEJM199808203390801
    1. Rutten FH, Zuithoff NP, Hak E et al. . Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880–7. 10.1001/archinternmed.2010.112
    1. Bhatt SP, Wells JM, Kinney GL et al. . beta-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016;71:8–14. 10.1136/thoraxjnl-2015-207251
    1. Farland MZ, Peters CJ, Williams JD et al. . beta-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother 2013;47:651–6. 10.1345/aph.1R600
    1. Short PM, Lipworth SI, Elder DH et al. . Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011;342:d2549 10.1136/bmj.d2549
    1. Lin R, Peng H, Nguyen LP et al. . Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of ‘beta-blockers’ in a murine asthma model. Pulm Pharmacol Ther 2008;21:115–24. 10.1016/j.pupt.2007.06.003
    1. Tivenius L. Effects of muliple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease. Scand J Respir Dis 1976;57:190–6.
    1. Fogari R, Zoppi A, Tettamanti F et al. . Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990;4:1145–9. 10.1007/BF01856511
    1. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005(4):CD003566 10.1002/14651858.CD003566.pub2
    1. Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:715–20. 10.1164/rccm.201208-1565OC
    1. Albert RK, Connett J, Bailey WC et al. . Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689–98. 10.1056/NEJMoa1104623
    1. Criner GJ, Connett JE, Aaron SD et al. . Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014;370:2201–10. 10.1056/NEJMoa1403086
    1. Qaseem A, Wilt TJ, Weinberger SE et al. . Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179–91. 10.7326/0003-4819-155-3-201108020-00008
    1. O'Reilly J, Jones MM, Parnham J et al. . Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010;340:c3134 10.1136/bmj.c3134
    1. Yancy CW, Jessup M, Bozkurt B et al. , Writing Committee Members. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240–327. 10.1161/CIR.0b013e31829e8776
    1. Fihn SD, Gardin JM, Abrams J et al. . 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;60:e44–e164. 10.1016/j.jacc.2012.07.013
    1. Niewoehner DE, Rice K, Cote C et al. . Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317–26. 10.7326/0003-4819-143-5-200509060-00007
    1. Anthonisen NR, Manfreda J, Warren CP et al. . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204. 10.7326/0003-4819-106-2-196
    1. Salpeter SR, Ormiston TM, Salpeter EE et al. . Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003;97:1094–101. 10.1016/S0954-6111(03)00168-9
    1. Hjalmarson A, Goldstein S, Fagerberg B et al. . Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283: 1295–302.
    1. Aaron SD, Fergusson D, Marks GB et al. . Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax 2008;63:122–8. 10.1136/thx.2007.082636
    1. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:842–6. 10.1164/rccm.200508-1338PP
    1. Mainous AG III, Koopman RJ, Diaz VA et al. . A coronary heart disease risk score based on patient-reported information. Am J Cardiol 2007;99:1236–41. 10.1016/j.amjcard.2006.12.035
    1. Malerba M, Ragnoli B, Salameh M et al. . Sub-clinical left ventricular diastolic dysfunction in early stage of chronic obstructive pulmonary disease. J Biol Regul Homeost Agents 2011;25: 443–51.
    1. Barr RG, Bluemke DA, Ahmed FS et al. . Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010;362:217–27. 10.1056/NEJMoa0808836
    1. Yawn BM, Kalhan Y, Rennard S et al. . COPD9USA June 2015. Chron Obstruct Pulmon Dis (Miami, Florida) 2015;2:343–66. 10.15326/jcopdf.2.4.2015.0147
    1. Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med 2012;106:1134–8. 10.1016/j.rmed.2012.04.007
    1. Warnier MJ, Rutten FH, de Boer A et al. . Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS ONE 2014;9:e105152 10.1371/journal.pone.0105152
    1. Chhabra SK, Gupta M, Ramaswamy S et al. . Cardiac sympathetic dominance and systemic inflammation in COPD. Copd 2015;12: 552–9. 10.3109/15412555.2014.974743
    1. Egan BM, Basile J, Chilton RJ et al. . Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich) 2005;7: 409–16. 10.1111/j.1524-6175.2005.04486.x
    1. Au DH, Curtis JR, Every NR et al. . Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 2002;121:846–51. 10.1378/chest.121.3.846
    1. Chiarella SE, Soberanes S, Urich D et al. . beta(2)-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis. J Clin Invest 2014;124:2935–46. 10.1172/JCI75157
    1. Nguyen LP, Omoluabi O, Parra S et al. . Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008;38: 256–62. 10.1165/rcmb.2007-0279RC
    1. Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis 2009;3:329–34. 10.1177/1753944709339968
    1. Agostoni P, Contini M, Cattadori G et al. . Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail 2007;9:827–33. 10.1016/j.ejheart.2007.04.006
    1. Jabbour A, Macdonald PS, Keogh AM et al. . Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010;55:1780–7. 10.1016/j.jacc.2010.01.024
    1. Camsari A, Arikan S, Avan C et al. . Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003;18:188–92. 10.1007/s00380-003-0706-z
    1. Schimmer JJ, Billups SJ, Delate T. Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting. Pharm Pract (Granada) 2009;7:205–12. 10.4321/S1886-36552009000400003
    1. Baber N. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Br J Clin Pharmacol 1994;37:401–4. 10.1111/j.1365-2125.1994.tb05705.x

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться